ACAM2000
| Vaccine description | |
|---|---|
| Target disease | Smallpox |
| Type | ? |
| Clinical data | |
| AHFS/Drugs.com | acam2000 |
| Pregnancy category |
|
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | none |
| ChemSpider | none |
ACAM2000 is a smallpox vaccine developed by Acambis. It was approved for use in the United States by the U.S. Food and Drug Administration (FDA) on 31 August 2007. It contains live vaccinia virus, cloned from the same strain used in an earlier vaccine, Dryvax. While the Dryvax virus was cultured in the skin of calves and freeze-dried, ACAM2000s virus is cultured in kidney epithelial cells (Vero cells) from an African green monkey. Efficacy and adverse reaction incidence are similar to Dryvax.[1] The vaccine is not routinely available to the US public; it is, however, used in the military and maintained in the Strategic National Stockpile.[2]
References
- ↑ Metzger W, Mordmueller BG (2007). "Vaccines for preventing smallpox". Cochrane Database Syst Rev (3): CD004913. doi:10.1002/14651858.CD004913.pub2. PMID 17636779.
- ↑ FDA/CBER Questions and Answers; Medication Guide; accessed 1 March 2008.
External links
This article is issued from Wikipedia - version of the 10/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.